Company / Current Liabilities
Monte Rosa Therapeutics, Inc. Current Liabilities History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$156.9M
FY2024
5-year range
$16.6M / $156.9M
FY2020-FY2024
Trend
+236.9%
vs FY2023
Sector context
#68 of 213
Health Care
What the data says
Current Liabilities changed +237% YoY in FY2024, a notable deviation from the 4-year average annual change of +82%.
Based on SEC 10-K filings.
$157M in FY2024 with a 3-year CAGR of +111.3%.
Increased from $26M to $157M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +111.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#146 of 213 in Health CareTop 68% of 213This company $156.9M Sector average $1.6B
▼
-90.1% below sector average
Key checks
Key Insights
- Monte Rosa Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 3-year CAGR of +111.3%, indicating consistent growth.
- In FY2024, current liabilities increased 236.9% year-over-year.
- Ranks #68 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $156.9M | +236.9% |
| FY2023 | $46.6M | +82.2% |
| FY2022 | $25.6M | +53.7% |
| FY2021 | $16.6M | -43.2% |
| FY2020 | $29.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026